The constructed network pharmacology revealed the significant interaction among the predicted targets that identified eight anti-HCC core targets (SRC, EGFR, CASP3, MMP9, mTOR, HIF1A, ERBB2, and PPARG) as the active bio targets of nitazoxanide in HCC. The gene discussed is CASP3; the disease is hepatocellular carcinoma.